Figure 3. Frequency, overlap, and relative survival glioblastomas (GBs) (includes GB and all GB variants including gliosarcoma) based on molecular profile.

Relative frequency of G-CIMP status, gene expression profiles, IDH1 mutation, and MGMT promoter methylation in GBs. IDH1 mutation and G-CIMP are depicted as discrete categories while gene expression and MGMT methylation status are depicted as a continuum. GBs with PN gene expression profiles and IDH1 mutations cluster almost exclusively within G-CIMP GBs and have improved clinical outcomes (left side of figure, see also table 1). Mesenchymal GBs are exclusively non-G-CIMP and IDH1 wild-type and have inferior clinical outcomes (see also table 1). G-CIMP = CpG hypermethylator phenotype; IDH1 mut = isocitrate dehydrogenase 1 gene mutation; IDH1 wt = isocitrate dehydrogenase 1 wild-type gene.